CoChat

Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma

Reni, Michele, Cereda, Stefano, Balzano, Gianpaolo, Passoni, Paolo, Rognone, Alessia, Fugazza, Clara, Mazza, Elena, Zerbi, Alessandro, Di Carlo, Valerio, Villa, Eugenio · 2009 · Cancer
Cited by 125

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Radiologic assessment of tumor response in pancreatic cancer is complicated by desmoplastic reactions within or around the tumor. The objective of this study was to evaluate the correlation between a decline in carbohydrate antigen 19‐9 (CA 19‐9) and survival in patients with advanced pancreatic cancer who received upfront chemotherapy. METHODS: CA 19‐9 serum basal values were measured in 247 patients with advanced pancreatic cancer who were enrolled in 5 consecutive trials between 1997 and 2007. Survival curves were compared among patients who had a predefined CA 19‐9 nadir variation (<50%. Group 1; 50% to 89%, Group 2; or >89%, Group 3). To eliminate guarantee‐time bias, survival analysis was repeated using the landmark method. RESULTS: In both univariate and multivariate analysis, the basal CA 19‐9 value significantly predicted survival. The median survival was 15.5 months for 34 patients who had normal basal CA 19‐9 values, 11.9 months for 108 patients who had basal values between 38 U/mL and 1167 U/mL, and 8 months for 105 patients who had basal values >1167 U/mL. At least 1 CA 19‐9 follow‐up value was available for 204 patients who had baseline values greater than normal. A significant difference in overall survival was observed in univariate and multivariate analyses between Groups 1 and 2, between Groups 1 and 3, and between Groups 2 and 3. The results were confirmed using the landmark method. CONCLUSIONS: In this study, baseline CA 19‐9 was confirmed as an independent prognostic factor for survival, and it may be considered as a stratification factor in trials in patients with advanced pancreatic cancer. Biochemical response may be used as a complementary measure to radiologic response to provide a better assessment of chemotherapy activity and to drive treatment decisions in clinical practice. Cancer 2009. © 2009 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.24302

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 125

Metadata

Authors
Reni, M., Cereda, S., Balzano, G., Passoni, P., Rognone, A., Fugazza, C., Mazza, E., Zerbi, A., Di Carlo, V., & Villa, E.
Venue
Cancer
Publisher
Wiley
Published
2009-06-04
Volume
115
Issue
12
Pages
2630-2639
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1987329654
Cited by
125
References
1
FWCI
4.48
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma. https://app.cochat.ai/papers/10.1002/cncr.24302
The paper
Reni, M., Cereda, S., Balzano, G., Passoni, P., Rognone, A., Fugazza, C., Mazza, E., Zerbi, A., Di Carlo, V., & Villa, E. (2009). Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer. https://doi.org/10.1002/cncr.24302

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.